Sanofi: No 'major' U.S. deal presented to board

Hearing rumors that Sanofi-Aventis was looking at a "major" U.S. acquisition? Well, Sanofi denied it presented said acquisition plan to its board, after Les Echos newspaper reported that the drugmaker's major shareholders had deemed the deal too risky. Report


Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.